Please ensure Javascript is enabled for purposes of website accessibility

Why Endo International plc Jumped and Then Faded -- Twice

By Brian Orelli, PhD - Oct 31, 2017 at 1:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker can't sustain a rally despite solid third quarter preliminary results.

What happened

Endo International (ENDP 22.42%) was up as much as 13.6% Tuesday before settling down to about half that gain after reporting preliminary third-quarter revenue and earnings results on Monday. The drugmaker can't seem to sustain a rally since Endo's shares did the same thing Monday, shooting up as much as 18% before ending the day up just 1.4%.

So what

Endo said third-quarter revenue came in at about $785 million with a loss of approximately $0.45 per share on a GAAP from continuing operations basis. Looking at adjusted earnings from continuing operations, Endo will post a profit of $0.85 per share.

The company also reaffirmed its revenue guidance for the year of between $3.38 billion and $3.53 billion. Endo's adjusted earnings from continuing operations are expected to be at the upper end of the guidance given in August of $3.35 to $3.65 per share.

Endo also noted that it plans to defend and protect its Vasostrict franchise from competition, pointing to a lawsuit filed against the FDA asking the court to make the agency stop the non-sterile-to-sterile bulk compounding of vasopressin, the active ingredient in Vasostrict. Endo recently got three patents issued for Vasostrict, which bring the total patents to five, all of which expire in 2035.

A virtual graph going up and down.

Image source: Getty Images.

Now what

Investors will have to wait until Nov. 9 to see the full results, but it's clear the third quarter was a solid one for Endo. It's likely that the stock didn't take off because it wasn't a breakout quarter -- management, for example, didn't raise 2017 guidance.

Considering all the struggles that Endo has had this year -- shares are down more than 60% year to date -- it seems reasonable for investors to take a wait-and-see attitude toward the drugmaker, especially with the uncertainty with Vasostrict hanging over its head.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Endo International plc Stock Quote
Endo International plc
$0.57 (22.42%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.